Vascular Endothelial Growth Factor, thrombelastography and coagulation in the context of etiology, outcome and clinical course of patients after circulatory arrest - VEPCA

开始日期2024-02-01

申办/合作机构-

100 项与 Vascular endothelial growth factor(National Institute of Health, Islamabad) 相关的临床结果

登录后查看更多信息

100 项与 Vascular endothelial growth factor(National Institute of Health, Islamabad) 相关的转化医学

登录后查看更多信息

100 项与 Vascular endothelial growth factor(National Institute of Health, Islamabad) 相关的专利（医药）

登录后查看更多信息

584

项与 Vascular endothelial growth factor(National Institute of Health, Islamabad) 相关的文献（医药）

2025-12-01·Neural Regeneration Research

A vascular endothelial growth factor–loaded chitosan-hyaluronic acid hydrogel scaffold enhances the therapeutic effect of adipose-derived stem cells in the context of stroke

Article

作者: Wu, Zhiyun ; Lin, Qiang ; Zhao, Zijun ; Zheng, Zhijian ; Liu, Nan ; Wu, Wenwen ; Liu, Ji ; Lin, Xiaohui ; Chen, Manli ; Chen, Hongbin

JOURNAL/nrgr/04.03/01300535-202512000-00028/figure1/v/2025-01-31T122243Z/r/image-tiff Adipose-derived stem cell, one type of mesenchymal stem cells, is a promising approach in treating ischemia-reperfusion injury caused by occlusion of the middle cerebral artery. However, its application has been limited by the complexities of the ischemic microenvironment. Hydrogel scaffolds, which are composed of hyaluronic acid and chitosan, exhibit excellent biocompatibility and biodegradability, making them promising candidates as cell carriers. Vascular endothelial growth factor is a crucial regulatory factor for stem cells. Both hyaluronic acid and chitosan have the potential to make the microenvironment more hospitable to transplanted stem cells, thereby enhancing the therapeutic effect of mesenchymal stem cell transplantation in the context of stroke. Here, we found that vascular endothelial growth factor significantly improved the activity and paracrine function of adipose-derived stem cells. Subsequently, we developed a chitosan-hyaluronic acid hydrogel scaffold that incorporated vascular endothelial growth factor and first injected the scaffold into an animal model of cerebral ischemia-reperfusion injury. When loaded with adipose-derived stem cells, this vascular endothelial growth factor–loaded scaffold markedly reduced neuronal apoptosis caused by oxygen-glucose deprivation/reoxygenation and substantially restored mitochondrial membrane potential and axon morphology. Further in vivo experiments revealed that this vascular endothelial growth factor–loaded hydrogel scaffold facilitated the transplantation of adipose-derived stem cells, leading to a reduction in infarct volume and neuronal apoptosis in a rat model of stroke induced by transient middle cerebral artery occlusion. It also helped maintain mitochondrial integrity and axonal morphology, greatly improving rat motor function and angiogenesis. Therefore, utilizing a hydrogel scaffold loaded with vascular endothelial growth factor as a stem cell delivery system can mitigate the adverse effects of ischemic microenvironment on transplanted stem cells and enhance the therapeutic effect of stem cells in the context of stroke.

2025-11-01·Current Diabetes Reviews

Exploring the Therapeutic Potential of Anti-VEGF Drugs for the Management of Diabetic Retinopathy: An Overview

Article

作者: Gowthamarajan, Kuppusamy ; Khandelwal, Aman ; Nirmal, Jayabalan ; Ponnusankar, S.

The discovery of antivascular endothelial growth factor medications has resulted in a substantial change in diabetic retinopathy treatment. The most common cause of diabetic retinopathy blindness is Diabetic Macular Edema. The pathophysiology of Diabetic Macular Edema is thought to include the well-known pro-angiogenic and pro-permeability factor vascular endothelial growth factor. Over the past decade, drugs that impede the functions of vascular endothelial growth factors have established themselves as a standard-of-care treatment for a range of ocular ailments and improved patients' clinical results with diabetic retinopathy and Diabetic Macular Edema, and their frequency has grown exponentially with the introduction of these agents Pegaptanib, Ranibizumab, and Aflibercept which are approved for ophthalmic indications, while Bevacizumab is used off-label. These medications delivered intravitreally have halted the vascular development of diabetic retinopathy. Various randomized trials have proven that antivascular endothelial growth factor medication is safe and effective in preserving vision. Following an extensive period of preclinical development aimed at enhancing and defining its biological impacts, these drugs were shown in clinical trials to be effective in treating diabetic retinopathy and other ophthalmic conditions. Data from various sources suggest that Pegaptanib, Ranibizumab, and Aflibercept are costly, while Bevacizumab is cost-effective, and in low and middle-income nations, it is thus a desirable therapy choice. However, issues with compounding, counterfeiting, and off-label usage restrict its availability in many nations. The pharmacology, pharmacokinetics, pharmacodynamics, adverse effects, and contraindications of antivascular endothelial growth factor agents are discussed, and the results of clinical trials evaluating their efficacy are summarized.

2025-03-01·Retina

FOUR-YEAR OUTCOMES AFTER INTRAVITREAL AFLIBERCEPT FOR MACULAR NEOVASCULARIZATION IN PATIENTS WITH PATHOLOGIC MYOPIA

Article

作者: Uramoto, Kengo ; Ohno-Matsui, Kyoko ; Mizuno-Onishi, Yuka ; Nagaoka, Natsuko ; Igarashi, Tae ; Yoshida, Takeshi ; Kaneko, Yuichiro

Purpose:The natural course of the visual acuity in eyes with myopic macular neovascularization is poor. Intravitreal injections of anti-vascular endothelial growth factor agents have demonstrated safety and efficacy in the short term for managing myopic macular neovascularization. The purpose of this study was to determine the 4-year outcomes of intravitreal aflibercept injections.Methods:A retrospective monocentric study including 49 eyes of 48 patients diagnosed with myopic macular neovascularization. These patients underwent treatment with intravitreal aflibercept using the pro re nata regimen after the first injection. The minimum follow-up duration was 4 years.Results:The patients had an average age of 63.8 years and an average axial length of 29.7 mm. The mean number of intravitreal aflibercept injections was 1.6, and 30 eyes (61.2%) had a single injection. At the baseline and at 1, 2, 3, and 4 years, the mean best-corrected visual acuities were 20/45, 20/41, 20/43, 20/51, and 20/53, respectively. The differences in the best-corrected visual acuity at the different times from that at the baseline were not significant.Conclusion:Intravitreal aflibercept therapy with the pro re nata regimen provides a 4-year visual benefit in eyes with myopic macular neovascularization, and it is better than the reported natural course in maintaining the best-corrected visual acuity.

100 项与 Vascular endothelial growth factor(National Institute of Health, Islamabad) 相关的药物交易

登录后查看更多信息

研发状态

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


EULAR2016	N/A	巨细胞动脉炎 Vascular endothelial growth factor (VEGF)	-	VASCULAR ENDOTHELIAL GROWTH FACTOR (GCA patients)	鹹淵鏇構觸憲醖鏇築製(夢顧淵選築衊鬱襯鹽鏇) = 壓鏇築糧選鬱醖獵憲選簾壓繭鑰壓鏇淵鹹鹽選 (醖襯襯鑰繭顧積膚糧糧, 631 ~ 1110)	-	2016-06-08
				VASCULAR ENDOTHELIAL GROWTH FACTOR (Controls)	鹹淵鏇構觸憲醖鏇築製(夢顧淵選築衊鬱襯鹽鏇) = 網遞網淵鏇顧範願衊窪簾壓繭鑰壓鏇淵鹹鹽選 (醖襯襯鑰繭顧積膚糧糧, 328 ~ 625)
ASCO2013	N/A	黑色素瘤	32	vascular endothelial growth factor (VEGF) (Stage IV melanoma patients)	鑰齋繭觸網繭襯蓋艱獵(鏇醖糧選簾範餘鹽獵範) = 觸淵夢繭鏇範選醖膚膚網繭觸鏇廠獵範壓繭鏇 (觸觸遞鹽醖醖鬱繭壓構 )	-	2013-05-20
ARVO2009	N/A	近视脉络膜新生血管 vascular endothelial growth factor (VEGF)	-	Vascular Endothelial Growth Factor (Eyes with myopic choroidal neovascularization (mCNV))	齋觸襯鏇壓蓋壓餘構艱(憲獵壓衊願憲鬱選衊餘) = 網憲壓糧選醖繭觸夢膚觸鑰壓夢廠蓋襯醖顧膚 (糧廠觸鬱夢糧淵製廠獵 )	-	2009-04-01
				Vascular Endothelial Growth Factor (Control group (patients with cataract without other ocular or systemic diseases))	齋觸襯鏇壓蓋壓餘構艱(憲獵壓衊願憲鬱選衊餘) = 築憲製膚鑰顧鏇窪夢糧觸鑰壓夢廠蓋襯醖顧膚 (糧廠觸鬱夢糧淵製廠獵 )
ARVO2008	N/A	早产儿视网膜病变 vascular endothelial growth factor (VEGF)	6	Vascular Endothelial Growth Factor (Stage 4A eyes)	窪築製衊製觸簾襯範鹹(窪遞遞鑰網築鬱鹽觸顧) = 鹽觸積憲窪範壓鑰鹽憲簾構艱鏇顧廠鹹膚糧衊 (齋選膚網鏇夢膚襯壓網 )	-	2008-05-01
				Vascular Endothelial Growth Factor (Stage 4B eyes)	窪築製衊製觸簾襯範鹹(窪遞遞鑰網築鬱鹽觸顧) = 築積繭壓壓遞憲窪鑰鹽簾構艱鏇顧廠鹹膚糧衊 (齋選膚網鏇夢膚襯壓網 )
EULAR2006	N/A	白塞病/贝赫切特综合征 VEGF	-	VASCULAR ENDOTHELIAL GROWTH FACTOR (Behcet's Disease Patients)	(廠製窪憲廠積窪構獵鹽) = 觸簾顧簾夢蓋淵構襯範遞襯觸鹹鑰繭糧製壓遞 (願繭膚糧齋膚顧鏇餘醖 ) 更多	-	2006-06-21
				VASCULAR ENDOTHELIAL GROWTH FACTOR (Healthy Controls)	(廠製窪憲廠積窪構獵鹽) = 選鏇憲觸醖網鑰糧獵築遞襯觸鹹鑰繭糧製壓遞 (願繭膚糧齋膚顧鏇餘醖 ) 更多
ARVO2005	N/A	-	-	10mM MG132	窪齋繭夢襯蓋衊鑰鏇糧(鬱壓糧憲淵艱鹽壓鹽鏇) = 築顧鹽膚醖簾築壓壓繭夢壓網觸鹽艱襯願獵範 (憲繭獵鑰繭齋淵膚遞獵 ) 更多	-	2005-05-01
				Vascular Endothelial Growth Factor (Control (no treatment))	鬱遞蓋築糧構鏇顧簾觸(觸鹽鏇憲憲壓齋壓選觸) = 網觸網鑰網顧築鏇糧願網鬱願糧膚顧範艱觸觸 (蓋夢糧餘襯襯簾獵鹹餘 )